GEN-2 TRIAL · ENROLLING Q2 2026
Bring better outcomes to your patients.
We are onboarding rehabilitation clinics in Ontario and Massachusetts for the Gen-2 clinical trial. Enrollment is open now.
Request investor brief →
Deck available
Market 1 · Entry wedge
$1.4B
Prosthetics today.
57 million people globally with upper-limb differences. Current functional devices cost $60K and fail 50% of users within a year. Established reimbursement in Canada (ADP) and the US (VA, Medicare HCPCS). The market exists and is paying — the product doesn't work.
$1.4B TAM
Reimbursed
Regulatory path exists
50% abandonmen
Market 1 · Entry wedge
$38B
Humanoid robotics by 2035.
Dexterous manipulation is the open problem every major robotics program is blocked on. Same actuators, same AI — different form factor. The prosthetic platform IS the humanoid end-effector. No re-engineering required: a socket swap and an SDK unlock a second market an order of magnitude larger.
$38B TAM
Same hardware
No re-certification
Data moat
Awards
Over 16+ Awards including:
Why Now
Three structural shifts made this possible in 2026.
01
ML inference is cheap enough to run on-device.
Grip classification that required a server rack in 2018 runs on an embedded microcontroller today. Real-time intent recognition without cloud latency is now a product feature, not a research aspiration.
→
02
Multi-material 3D printing reached production tolerances.
The ability to co-print rigid structure, compliant skin, and conductive traces in a single run — at repeatable tolerances — only reached clinical viability in the last two years. This is the manufacturing unlock that makes per-user customization economically viable.
→
03
Reimbursement expansion is actively underway.
Canada ADP raised its myoelectric funding cap. US VA expanded prosthetics coverage. CMS is reviewing HCPCS L-codes for AI-assisted devices. The payer environment has never been more favorable for a new entrant with clinical evidence.
→
Traction
What we have already proven
4
Clinical sites
Gen-1 units active in rehab clinics as of January 2025.
17
Degrees of freedom
Validated in hardware. 6–10× the actuation of market leaders.
~2K
Grip events / day
Per deployed hand. Training data collection is live.
$0
Cost to clinics
Trial devices placed at no charge. Revenue model begins Gen-2.
Reimbursement pathways
From referral to outcomes data in three steps.
The Better Bionics hand is designed around existing reimbursement frameworks — not against them. We are not asking payers to create a new category.
CANADA
Provincial MSP
BC, AB, QC programs cover functional myoelectric devices.
CANADA
Provincial MSP
BC, AB, QC programs cover functional myoelectric devices.
USA
Provincial MSP
BC, AB, QC programs cover functional myoelectric devices.
USA
Provincial MSP
BC, AB, QC programs cover functional myoelectric devices.
Building hands that work for people, and
for the robots that will work alongside them.
Product
Gen-2 hand
Clinical program
Research access
Company
About
Contact
Legal
Privacy
Terms
Health Canada
FDA registration
© 2026 Better Bionics Inc. · Toronto, Canada
Medical device · Health Canada & FDA pending